Blue Earth Diagnostics is highlighting clinical results for its Posluma (flotufolastat F-18) PET radiotracer that will be presented at the upcoming American Society for Radiation Oncology (ASTRO) annual meeting in San Diego.
Posulma is indicated for prostate-specific membrane antigen (PSMA)-PET imaging in men with prostate cancer with suspected metastasis. At the meeting, researchers will present further data from phase III trials. In addition, Blue Earth will host an industry-expert theater event titled, "Posluma: Precision PET Imaging that is Truly Revealing."
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
